Previous 10 | Next 10 |
2023-06-27 05:14:31 ET Summary Biogen will find out in July if the FDA has granted its Alzheimer's drug Leqembi full approval. After the Aduhelm fiasco, Biogen has much to prove in the AD space. Partner Eisai has been handling the approval push and launch - more successfully s...
2023-06-23 07:30:00 ET It was two years ago that Biogen 's (NASDAQ: BIIB) stock soared to more than $400 on news that its Alzheimer's treatment, Aduhelm (aducanumab), had obtained accelerated approval from the Food and Drug Administration (FDA). Today, however, the company has g...
2023-06-21 11:02:52 ET The leading drug industry trade group Pharmaceutical Research and Manufacturers of America (PhRMA) filed a lawsuit against the U.S. government on Wednesday, challenging the drug pricing negotiations introduced by the recently-enacted Inflation Reduction Act. The N...
2023-06-20 06:58:24 ET Summary Ionis Pharmaceuticals' phase 2 study showed that patients treated with donidalorsen through week 17 achieved a 90% reduction in hereditary angioedema attack compared to placebo; the second dose brought a 97% reduction. Clinical trial results from the...
2023-06-19 05:30:00 ET Biogen (NASDAQ: BIIB) recently got some good news in the U.S. An advisory committee for the Food and Drug Administration (FDA) unanimously confirmed the clinical benefit of its Alzheimer's drug, Leqembi. The FDA earlier granted Leqembi accelerated approval and...
2023-06-19 05:16:46 ET Summary Pharma/biotechnology and healthcare providers are slightly undervalued relative to 11-year averages. Healthcare equipment is the most overvalued subsector. Fast facts on PBE, a genomics ETF. 10 healthcare stocks cheaper than their peers in Ju...
2023-06-17 10:07:00 ET For those seeking stocks that have trounced the market over the past year, the biotech sector might be an excellent place to start. The SPDR S&P Biotech Index ETF , an industry benchmark, has climbed 34% over the trailing-12-month period, nearly three times th...
2023-06-12 18:23:15 ET Biogen ( NASDAQ: BIIB ) said that three of its board members will no longer stand for reelection at the company's upcoming annual meeting, which it plans to adjourn until June 26. The biotech company said Alexander Denner, William Jones and Richard Mulliga...
Biogen Will Adjourn Its Annual Meeting of Stockholders Until June 26, 2023, to Give All Stockholders Sufficient Time to Review and Vote on Proposed Slate CAMBRIDGE, Mass., June 12, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced several changes to its Board of Directors ...
2023-06-11 12:00:02 ET Driven by novel therapeutics from Biogen ( NASDAQ: BIIB )/ Eisai ( OTCPK:ESALF ) and Eli Lilly ( NYSE: LLY ), the Alzheimer’s disease market across eight major countries will reach $13.7B in 2030, the data analytics firm, GlobalData said las...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases ...
TOKYO and CAMBRIDGE, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today tha...
NEW YORK, NY / ACCESSWIRE / June 12, 2024 / Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq:BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to obtain additional information by visiting ...